Fig. 1
From: MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy
MUC1 interacts with several oncogenic pathways like NF-κB. It can activate TGFβ-activated Kinase (TAK) directly and activated NFκB pathway promotes survival and metastasis in BC cells. Besides, MUC1-CD is necessary for TWIST activation and it correlates to overexpression of cyclin D in BC cells. Moreover, MUC1-CD inhibits P53 activity in BC cells, thus it blocks apoptosis in these cells. MUC1-CD has wide range of interactions with different oncogenic and apoptotic molecules. In general, it promotes cell proliferation and resistance to apoptosis in BC cells